Hospital
Lehigh Valley Hospital- Pocono
Lehigh Valley Hospital- Pocono was paid $3.75M by Medicaid between May 2022 and Dec 2024, across 79 billing codes. Its largest line is 99284, emergency room visit (serious) — 46% of everything it billed.
33Billing provider infoLEHIGH VALLEY HOSPITAL- POCONO
DICKSON CITY, PA 18519
DICKSON CITY, PA 18519
33aNPI1396402053assigned 11/17/2021
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.75M
24GClaims90,352
24DCodes billed79
24AFirst – last monthMay 2022 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#71 of 154
Median peer was paid$2.82M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official THOMAS, ROBERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 11,774 | $575K | |
| 2023 | 40,905 | $1.60M | |
| 2024incomplete | 37,673 | $1.58M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 46% | 11,494 | 11,119 | $1.72M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 6,909 | 6,722 | $737K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 2,189 | 2,119 | $398K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 9.2% | 3,265 | 3,138 | $346K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.2% | 1,007 | 979 | $158K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 2,637 | 2,518 | $66K |
| 80053 | Comprehensive metabolic panel | 1.7% | 6,722 | 6,439 | $65K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 7,724 | 7,397 | $40K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,611 | 1,490 | $26K |
| 84703 | <1% | 2,227 | 2,158 | $21K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,314 | 2,228 | $19K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,811 | 1,688 | $19K |
67 more codes
| 84484 | <1% | 1,552 | $16K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 259 | $15K |
| 83690 | <1% | 2,495 | $10K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 108 | $10K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 838 | $8K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 127 | $7K |
| 71045 | Radiologic examination, chest; single view | <1% | 980 | $7K |
| 83880 | <1% | 230 | $7K | |
| 83735 | <1% | 1,060 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 816 | $5K |
| 81003 | <1% | 1,869 | $5K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 134 | $5K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 279 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 535 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 64 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 340 | $3K |
| 81001 | <1% | 1,239 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 65 | $3K |
| 80076 | <1% | 337 | $3K | |
| 85379 | <1% | 258 | $2K | |
| 83605 | <1% | 212 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 20 | $962.51 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $676.63 |
| 85610 | <1% | 196 | $639.31 | |
| 97161 | <1% | 12 | $638.34 | |
| 85730 | <1% | 70 | $479.62 | |
| 73630 | <1% | 41 | $422.78 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12 | $383.30 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 14 | $255.30 |
| 73610 | <1% | 14 | $185.40 | |
| 86850 | <1% | 13 | $77.57 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 31 | $58.47 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 60 | $47.69 |
| 86901 | <1% | 14 | $42.87 | |
| 86900 | <1% | 14 | $42.31 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,897 | $3.15 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 2,213 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,538 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 99 | $0.00 |
| A9270 | Non-covered item or service | 0% | 935 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 544 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 219 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,193 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 361 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 1,831 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 97 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 49 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 75 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 52 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 31 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 3,570 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 789 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 2,168 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 42 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 50 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 163 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 3,746 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 1,777 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 68 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 120 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 240 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 119 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 12 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 29 | $0.00 |
| 90715 | 0% | 65 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 18 | $0.00 |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTHOMAS, ROBERT (CHIEF ACCOUNTING OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Millennium Health, LLC | San Diego, CA | $579.29M |
| Lehigh Valley Hospital | Allentown, PA | $64.40M |
| Lehigh Valley Hospital Pocono | East Stroudsburg, PA | $11.90M |
| Lehigh Valley Hospital Hazleton | Hazleton, PA | $11.69M |
| Lehigh Valley Hospital | Allentown, PA | $10.00M |
| Lehigh Valley Hospital - Schuylkill | Pottsville, PA | $6.83M |
| Lehigh Valley Hospital | Allentown, PA | $2.90M |
| Lehigh Valley Hospital | Allentown, PA | $1.95M |
| Lehigh Valley Hospital, INC | Allentown, PA | $1.85M |
| Lehigh Valley Hospital | Allentown, PA | $1.40M |
| Lehigh Valley Hospital - Schuylkill | Saint Clair, PA | $744K |
| Maryland Wound & Amputation Prevention, LLC | Lutherville, MD | $399K |
| Robert L Thomas MD FCCP LLC | Walterboro, SC | $253K |
| A-One Home Health Services, LLC | Everett, WA | $236K |
| Avamere Home Health Care, LLC | Bellingham, WA | $234K |
| Lehigh Valley Hospital Schuylkill | Pottsville, PA | $218K |
| Lehigh Valley Hospital Hazleton | Hazleton, PA | $193K |
| Prime Home Health, LLC | Federal Way, WA | $115K |
| Lehigh Valley Hospital | Allentown, PA | $70K |
| Northwest Hospice LLC | Tigard, OR | $33K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.